Compare RKDA & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | PTIX |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.0M |
| IPO Year | 2015 | 2016 |
| Metric | RKDA | PTIX |
|---|---|---|
| Price | $2.41 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.7K | ★ 149.6K |
| Earning Date | 11-07-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,173,000.00 | N/A |
| Revenue This Year | $21.31 | N/A |
| Revenue Next Year | $28.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.31 | N/A |
| 52 Week Low | $1.76 | $0.70 |
| 52 Week High | $6.71 | $14.28 |
| Indicator | RKDA | PTIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.25 | 24.67 |
| Support Level | $2.01 | $1.12 |
| Resistance Level | $3.50 | $1.68 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 29.49 | 3.50 |
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.